Clinical Trial Update: A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BMS-986504 as monotherapy and in combination for MTAP-deleted advanced or metastatic solid tumors; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BMS-986504

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Solid Tumors | Phase 2 | Status: NOT_YET_RECRUITING